Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | July 28, 2011

CardioGen Reveals Cardiac PET’s Soft Underbelly

Typically, the only radiation facing travelers is from the airport scanners they must walk through to board airplanes. Not so, however, for two travelers who set off radiation alarms when crossing the U.S. border earlier this month, an incident whose fallout threatens the future of cardiac PET.

Early this week the FDA warned U.S. healthcare providers to stop using the radioisotope generator commonly used to perform PET exams of the heart. Soon after Bracco Diagnostics, the maker of CardioGen-82, voluntarily recalled the cardiac generator (“FDA: Stop Using CardioGen-82 Due to Increased Radiation Exposure”).

An investigation by the FDA had found that CardioGen-82 had months earlier led to the dosing of the two travelers not only with rubidium-82,  the very short half-life isotope needed for their cardiac scans, but also with strontium, a much longer lived isotope. The inadvertent dosing, according to the FDA, was due to a failure in the manufacturing process called “strontium breakthrough.”

The resulting exposure of patients to excess radiation illustrates the vulnerability of imaging devices that depend on radioisotopes. Anyone familiar with nuclear cardiology, which depends heavily on the radioisotope technetium, understands how vulnerable these devices are.

An aging Canadian reactor with a distressingly long history of shutdowns supplies the molybdenum radioisotope that generate most of the technetium used in the U.S. for cardiac SPECT studies. When this reactor shut down, spurring a 15-month technetium shortage, PET advocates – led by Bracco Diagnostics – began recruiting nuclear cardiologists to switch from SPECT to PET. (“Time for a New Normal in Nuclear Cardiology?”). This alternative, they said, was not vulnerable to such shortages.  For those who were convinced, the recent news is not only ironic, but troubling.

In its warning to healthcare providers, the FDA noted that “the risk of harm from this exposure is minimal” and that “it would take much more radiation to cause any severe adverse health effects in patients.” (“CardioGen-82 PET Scan: Drug Safety Communication - Increased Radiation Exposure”)  Yet estimates derived from mathematical modeling done at the Los Alamos National Laboratory indicate that exposure for the two patients may be as high as 90 mSv – more than 30 times the normal dose of a cardiac PET scan. And it is not certain that these two patients are the only ones who have been so exposed. The FDA is now trying to find out how many, if any, more patients suffered excess radiation dose due to strontium breakthrough.

One question not being asked is why this unexpected exposure was detected at a U.S. border crossing instead of the PET suites where the scans were performed. Moreover, how could such excess doses occur in the first place? Are no tests required to ensure the purity of rubidium chloride before it is injected into patients?

Toward that end, the FDA is looking into the sufficiency of the testing procedures used to detect strontium breakthrough at clinical sites using CardioGen-82. Obviously, they are not sufficient, at least not everywhere. But they will have to be soon, or cardiac PET may have a tough time recovering from a shortage that should have never been.

Editor's note: For additional information about this incident and the product recall, visit www.cardiogen.com.

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Overlay Init